Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Participating in BIO-Europe Spring®

March 17, 2025

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

March 6, 2025

Enveric Biosciences CEO Issues Letter to Shareholders

February 27, 2025

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

February 25, 2025

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

February 4, 2025

Enveric Biosciences Announces Closing of $5 Million Public Offering

February 3, 2025

Enveric Biosciences Announces Pricing of $5 Million Public Offering

January 30, 2025

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

January 30, 2025

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

January 6, 2025

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

January 6, 2025

1
2
3
…
15
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.